About Us
Vision & Mission
Our Approach
Leadership
Contact
Medicines + Science
Product
Pipeline
Clinical Studies
Medical Research Grants
Serving Patient Communities
Patient Advocacy + Engagement
Areas of Focus
Sponsorships
Expanded Access Policy
Community Letters
Patient Stories
Working with Us
Culture and Values
Benefits
News + Insights
Blog
Press Releases
About Us
Vision & Mission
Our Approach
Leadership
Contact
Medicines + Science
Product
Pipeline
Clinical Studies
Medical Research Grants
Serving Patient Communities
Patient Advocacy + Engagement
Areas of Focus
Sponsorships
Expanded Access Policy
Community Letters
Patient Stories
Working with Us
Culture and Values
Benefits
News + Insights
Blog
Press Releases
Community Letters
ITF Therapeutics LLC announces commercial availability of DUVYZAT™ (givinostat) for the treatment of Duchenne muscular dystrophy